244 related articles for article (PubMed ID: 2079381)
41. [Comparative investigation of action and side effects in intravenous, intramuscular and oral application of fluphenazine dihydrochloride (author's transl)].
Maurer YA
Pharmakopsychiatr Neuropsychopharmakol; 1979 Sep; 12(5):366-74. PubMed ID: 504343
[TBL] [Abstract][Full Text] [Related]
42. [Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
Schilkrut R; Duran E; Haverbeck C; Katz I; Vidal P
Arzneimittelforschung; 1978; 28(9):1494-5. PubMed ID: 38807
[TBL] [Abstract][Full Text] [Related]
43. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
[TBL] [Abstract][Full Text] [Related]
44. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
45. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Kane J; Quitkin F; Rifkin A; Klein DF
Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
[TBL] [Abstract][Full Text] [Related]
47. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Klein A; Ehle G
Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
[TBL] [Abstract][Full Text] [Related]
48. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
[TBL] [Abstract][Full Text] [Related]
49. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
Leong OK; Wong KE; Tay WK; Gill RC
Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
[TBL] [Abstract][Full Text] [Related]
50. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
[TBL] [Abstract][Full Text] [Related]
51. [Fluspirilen and fluphenazine in schizophrenic patients. Comparative study].
Magnus RV
MMW Munch Med Wochenschr; 1980 Dec; 122(49):1758-60. PubMed ID: 6779147
[No Abstract] [Full Text] [Related]
52. Clinical experience with fluphenazine decanoate in the treatment of patients with long-standing chronic schizophrenia.
Christodoulidis H; Frangos H
Curr Ther Res Clin Exp; 1975 Jul; 18(1 pt 2):193-8. PubMed ID: 809234
[No Abstract] [Full Text] [Related]
53. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
[TBL] [Abstract][Full Text] [Related]
54. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
55. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
56. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
MacCrimmon DJ; Saxena B; Foley P; Grof P
Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
[TBL] [Abstract][Full Text] [Related]
57. Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.
Omi T; Mitsui Y; Matsunaga H
J Clin Pharm Ther; 2018 Feb; 43(1):117-120. PubMed ID: 28718220
[TBL] [Abstract][Full Text] [Related]
58. A two year trial of loxapine succinate in chronic psychotic patients.
Simpson GM; Branchey MH; Lee JH; Varga E
Dis Nerv Syst; 1976 May; 37(5):305-7. PubMed ID: 816626
[TBL] [Abstract][Full Text] [Related]
59. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
Raskind M; Alvarez C; Herlin S
J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
[TBL] [Abstract][Full Text] [Related]
60. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Altamura AC; Curry SH; Montgomery S; Wiles DH
Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
